A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

Summary

The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with the beta-lactam meropenem for the treatment of serious gram-negative bacterial infections. Adult male and female healthy participants will receive a single intravenous infusion of nacubactam co-administered with meropenem and then undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid (ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.

Timeline

Start

2017-06-15

Primary completion

2017-08-10

Completion

2017-08-10

Publications

• Morita J, Ishiwata K, Matsumoto S, Kato S, Attley G, Patel K, Rodriguez I, Mallalieu NL. Evidence of intrapulmonary penetration of nacubactam, a novel beta-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults. Antimicrob Agents Chemother. 2026 Jun 3;70(6):e0002626. doi: 10.1128/aac.00026-26. Epub 2026 Apr 30.

Drugs

Indications